Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025)

Lyra Therapeutics has reported EBT Margin over the past 5 years, most recently at 99271.43% for Q4 2025.

  • Quarterly results put EBT Margin at 99271.43% for Q4 2025, down 9402119.0% from a year ago — trailing twelve months through Dec 2025 was 7263.32% (down 117492.0% YoY), and the annual figure for FY2025 was 7263.32%, down 117492.0%.
  • EBT Margin for Q4 2025 was 99271.43% at Lyra Therapeutics, down from 23924.0% in the prior quarter.
  • Over the last five years, EBT Margin for LYRA hit a ceiling of 2545.09% in Q1 2022 and a floor of 129290.91% in Q4 2022.
  • Median EBT Margin over the past 5 years was 4846.51% (2021), compared with a mean of 22156.26%.
  • Biggest five-year swings in EBT Margin: crashed -12426619bps in 2022 and later soared 11892173bps in 2023.
  • Lyra Therapeutics' EBT Margin stood at 5024.72% in 2021, then plummeted by -2473bps to 129290.91% in 2022, then skyrocketed by 92bps to 10369.18% in 2023, then skyrocketed by 49bps to 5250.24% in 2024, then tumbled by -1791bps to 99271.43% in 2025.
  • The last three reported values for EBT Margin were 99271.43% (Q4 2025), 23924.0% (Q3 2025), and 4062.84% (Q2 2025) per Business Quant data.